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The aim was to evaluate the mismatch negativity (MMN) component, a correlate of the auto-
matic detection of changes in the acoustic environment, in healthy adults, and adults with
amnestic mild cognitive impairment (aMCI). Forty-three aMCI subjects and 43 healthy Chi-
nese older adults were arranged into experimental group and control group, respectively.
Their MMN amplitude and latency were measured at the FZ, FCZ, and CZ electrode sites
under a passive auditory oddball task.The results showed that the latencies obtained from
the FZ, FCZ, and CZ electrode sites were significantly longer in the aMCI adults than in
the control adults (P<0.01) while there were no significant differences in MMN amplitude
between two groups (P> 0.05).The MMN latency was found to be a sensitive and specific
biomarker of aMCI.
Keywords: amnestic mild cognitive impairment, Alzheimer’s disease, event-related potentials, mismatch
negativity, biomarkers
INTRODUCTION
Mild cognitive impairment (MCI) refers to the gray zone between
the cognitive changes of normal aging and very early demen-
tia (Grundman et al., 2004a; Stephan et al., 2013). Individuals
with MCI show cognitive impairment greater than expected for
their age, but otherwise are functioning independently and do not
meet the commonly accepted criteria for dementia (Petersen et al.,
1999).
The incidence of MCI ranges from 1 to 6% per year while preva-
lence estimates range from 3 to 22% per year in western developed
countries (Hanninen et al., 2002; Larrieu et al., 2002; Ganguli et al.,
2004; Roberts et al., 2012). Recently, one large cross-sectional study
(Jia et al., 2014) conducted in China, using a multistage cluster
sampling design, included a total of 10,276 community residents
(6096 urban, 4180 rural) aged 65 years or older, found a preva-
lence rate of 20.8% for MCI in Chinese elders. The study also
stated that rural population had a higher prevalence of overall MCI
than urban population (23.4 vs. 16.8%). CRCA (China Research
Center on Aging, 2014) has estimated that 1 of every 9 persons
is 65 years old or over, totaling 119 million people at the end of
2010 in China. By the year 2050, those numbers are projected to
double with the actual number of people over age 65 projected
to be almost 300 million, at which point the population of older
persons will be accounted for almost 22% of the Chinese popula-
tion (2014). As the high prevalence of MCI in Chinese rural elders
and the rate at which the Chinese population is aging has acceler-
ated, we can forecast that there would be a huge population (about
35.1 million) of elders with MCI by the year 2050 in the rural of
China. However, with the progressive urbanization of china, more
medical support will be supplied for urban meanwhile medical
resources will be even more sparse in rural areas. As a result, the
MCI patients in rural areas can hardly get medical help.
Among the different subtypes of MCI, amnestic mild cognitive
impairment (aMCI) is the most likely to progress to Alzheimer’s
disease (AD) (Albert et al., 2011), which is the most prevalent form
of dementia in the elderly (Papaliagkas et al., 2009). Subjects with
aMCI develop dementia at 10–15% per year (Grundman et al.,
2004b; Misra et al., 2009) as compared to the general popula-
tion of 1–2% (Bischkopf et al., 2002). Delaying or preventing the
onset of dementia by a mere 1 year alone could translate into one
million fewer number of cases than predicted by the year 2050
(Brookmeyer et al., 1998).
Thus, Biomarkers are needed to facilitate early identification
of aMCI and predict progression to dementia. The methods used
to search for biomarkers of aMCI include scales (Duchesne et al.,
2005; Hoops et al., 2009; Kasten et al., 2010), neuroimaging tech-
niques (Small et al., 2006; Hamalainen et al., 2007), cerebrospinal
fluid analysis (Perneczky et al., 2011), and genetic analysis (Zhang
et al., 2012), which are invasive or expensive or requires a high
level of education, could not be widely used in rural population.
Hence, the identification of objective biomarkers that are sensitive
to the pathophysiological changes in aMCI and easily accepted in
rural population is important for both prevention of dementia
and promotion of health.
Mismatch negativity (MMN) relates to the difference wave
obtained by subtracting the standard stimulus ERP from the
deviant stimulus ERP and usually peaks between 150 and 250 ms
after presentation of the deviant stimulus (Nagai et al., 2013). On
electroencephalogram (EEG), maximal MMN responses are evi-
dent at front central scalp recording sites, with phase reversal at
mastoids (Nagai et al., 2013).
Whether MMN technique would be such aMCI biomarkers
warrant consideration founded on three essential characteristics
designated as ideal (Lindin et al., 2013): it is non-invasive, simple to
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measure, and inexpensive. Moreover, MMN is even elicited under
passive conditions when subjects ignore the stimuli, which means
it does not need the cooperation of participants and it would not
be limited by educational level of participants.
Previous studies have shown that MMN is a promising bio-
marker candidate for cognitive impairment in Parkinson’s disease
(Cai et al., 2004), brain trauma (Wijnen et al., 2007), Alzheimer
disease (Tales et al., 2008), and schizophrenia (Umbricht and Krl-
jes, 2005). In these reported researches, the MMN latencies and
(or) amplitude were significantly different between experimen-
tal group and control group. Despite the increasing number of
research about MMN in other diseases, there are only two pub-
lished studies to date evaluating the effect of MCI on MMN
parameters. Mowszowski et al. (2012) recorded ERPs in an Aus-
tralia sample of 14 healthy adults and 28 adults with MCI, in
a passive oddball task in which the standard and deviant stim-
uli differed in duration (standard: 50 ms, deviant: 100 ms). They
did observe that at mastoid locations, the MMN amplitude was
smaller in the MCI group than in the control group, which the
authors considered reflect of the inefficiency of processing infor-
mation in an early pre-attentional stage in the MCI group. Lindin
et al. (2013) studied MMN component in Spain healthy adults and
adults with aMCI (age range: 50–87 years) using auditory–visual
attention–distraction task and found that MMN amplitude at the
Cz electrode site was significantly smaller in the aMCI adults than
in the control adults, suggesting MMN to be a sensitive and specific
biomarker of aMCI.
The recent two studies provided some interesting results, but
also presented some limitations. Thus, the former study obtained
MMN amplitude at mastoid electrodes, but not at the frontocen-
tral locations, where MMN is typically identified and analyzed
(Mowszowski et al., 2012); although the latter study obtained
MMN at the frontocentral locations, they only evaluated it at
the CZ electrode site, and did not take into account the possible
effects of interactions between the electrode sites (FZ, FCZ, CZ)
and Group factors (Lindin et al., 2013). Moreover, these two stud-
ies were carried out in Australia and Spain, respectively; further
researches would be needed in Chinese population.
The aims of the present study were as follows: (1) to deter-
mine any differences in MMN parameters between healthy adults
and adults with aMCI in Chinese rural population; (2) to evaluate
whether such differences between healthy adults and adults with
aMCI are affected by electrode sites, by considering three elec-
trode sites (FZ, FCZ, CZ); (3) to evaluate whether MMN changes
associated with aMCI are sensitive and specific biomarkers of this
syndrome.
MATERIALS AND METHODS
PARTICIPANTS
Forty-three aMCI subjects and 43 healthy Chinese older adults
selected from rural villages of Weifang, Shandong, China were
arranged into experimental group and control group, respectively.
Experimental group: there were 22 male and 21 female sub-
jects in this group, the average age was 65.81± 6.90 years and the
average years of education were 3.88± 2.80. The participants were
selected according to the U.S. mental disorders’ fourth edition of
the Diagnostic and Statistical Manual (DSM-IV) (Association and
DSM-IV, 1994) in mild neurocognitive damage standards and the
Diagnosis standard of Shanghai Mental Health Center (Shi Fu and
Wei, 1999): (1) memory complaints corroborated by an informant;
(2) Mini-Mental State Examination (MMSE) Score≤26 points, the
level of Global Deterioration Scale (GDS) assessment is between 2
and 3; (3) activity of daily living scale (ADL) Score≤18 points; (4)
Hachinski ischemia index (HIS)≤4 points; (5) course of cognitive
impairment >3 months; (7) Does not meet DSM-IV (1) criteria
for dementia syndrome.
Control group: there were 19 male and 24 female subjects in
this group, the average age was 66.21± 6.81 years and the average
years of education were 4.90± 2.76. The participants were selected
according to the following criteria: (1) no memory complaint; (2)
MMSE total score ≥24; (3) intact instrumental activities of daily
living.
Subjects with any of the following condition were excluded
from the study: (1) left-handed; (2) visual or hearing difficulty;
(3) depression; (4) history of head trauma; (5) heart, lung, liver,
or kidney failure; (6) active neurological or psychiatric conditions;
(7) any severe illness that may affect cognitive function; (8) drug
or alcohol abuse.
Ethical approval for this study was obtained from the Research
Ethics Committee, Weifang Medical University, and written
informed consents were obtained from all of the subjects.
There were no significant differences in gender, age, or educa-
tional level between the experimental and control groups as shown
in Table 1.
STIMULI AND TASK
A passive auditory oddball task was used in this study. Partici-
pants were presented with 500 auditory stimuli (divided in two
blocks separated by a 2-min rest interval). Auditory stimuli were
sounds, presented binaurally via headphones. Two kinds of sounds
were presented: 85% were standard stimuli (tone bursts, 1000 Hz,
85 dB) and 15% were deviant stimuli (tone bursts, 2000 Hz, 90 dB).
ELECTROENCEPHALOGRAPHIC RECORDING
The participants were seated on a comfortable chair in a Fara-
day chamber, with attenuated levels of light and noise, and were
instructed to move as little as possible during the recording. The
EEG was recorded from 64 ring electrodes placed in an elastic cap,
according to the International 10–20 system. All electrodes were
referenced to an electrode attached to the tip of the nose, and an
electrode positioned at Fpz served as ground. The vertical electro-
oculogram (EOG) was recorded from two electrodes placed supra
and infra-orbitally on the left eye, and the horizontal EOG was
recorded from two electrodes placed at the outer canthi of both
Table 1 | Characteristics of the study sample (aMCI vs. HC).
Variable aMCI HC P
Age 65.81±6.90 66.21±6.81 0.787
Female 21 (49%) 24 (56%) 0.517
Education (years) 3.88±2.80 4.90±2.76 0.093
aMCI, amnestic mild cognitive impairment; HC, healthy controls.
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eyes. The EEG was continuously digitized at a rate of 1000 Hz
(band pass 0.05–100 Hz), and electrode impedances were kept
below 5 kΩ. Finally, to identify and measure MMN, we obtained
the deviant minus standard (D− S) difference waveforms. The
MMN component was identified as a negative wave in the 100–
250 ms interval, and it was evaluated at the FZ, FCZ, and CZ
electrode sites, respectively. The MMN amplitude (in microvolts,
from the maximum peak to the baseline) and latency (in millisec-
onds, from the auditory stimulus onset to the maximum peak)
were measured.
STATISTICAL ANALYSIS
Repeated measure analysis of variance (ANOVA) was conducted
to investigate the effect of the Group (Experimental group, Con-
trol group) and Electrode Sites (FZ, FCZ, CZ) factors on the MMN
amplitude and latency. The comparison on various characteristics
was conducted using Student’s test (for continuous variables) or
chi-square test (for dichotomous variables). All statistical analy-
sis was performed using SPSS 18.0. Differences were considered
significant at p < 0.05.
RESULTS
MMN LATENCY
The grand average MMN wave forms for aMCI and healthy con-
trols are shown in Figure 1, healthy adults in the current study have
a negative-going MMN in the 100–250 ms time window at the FZ
and FCZ electrode while aMCI patients showed no clear MMN.
For MMN latency, repeated ANOVA (Group× Electrode Sites)
showed significant effects of the Electrode Sites factor (F = 61.984,
P < 0.001), the Group factor (F = 197.573, P < 0.001), and
the Group× Electrode Sites interaction (F = 11.728, P < 0.001)
(Table 2). The latencies obtained from the FZ, FCZ, and CZ
electrode sites were significantly longer in the MCI group than
in the control group (P< 0.05) (Table 3). For the aMCI group,
FZ latency> FCZ latency>CZ latency (P < 0.01); for the control
group, FZ latency>CZ latency (P < 0.01) and FCZ latency>CZ
latency (P < 0.01), but there was no significant difference between
FZ latency and FCZ latency (P> 0.05) (Table 3).
MMN AMPLITUDE
Repeated ANOVA (Group× Electrode Sites) showed significant
effects of the Electrode Sites factor (F = 25.770, P < 0.001),
but there was no significant Group factor (F = 0.688, P> 0.05)
or Group× Electrode Sites interaction (F = 2.586, P > 0.05)
(Table 2).
DISCUSSION
Mismatch negativity component was identified in both groups of
participants (control and aMCI). Control and aMCI adults showed
differences for MMN component, healthy adults in the current
study have a negative-going MMN with an evident peak in the
100–250 ms time window at the FZ electrode while aMCI patients
showed no clear MMN. However, when compared to the clear
MMN peak at−4µV at Cz in Lindin et al. (2013), the MMN here
in the healthy group seems to be not that prominent (−1.5µV).
The reason might be the sample differences of this study and
Mónica Lindínl’s. The average age of healthy adults in the cur-
rent study was 66.21± 6.81, while the clear MMN peak at −4µV
FIGURE 1 | Grand average MMN wave forms for aMCI and healthy
controls. Mismatch negativity (MMN) component was identified in both
groups of participants (control and aMCI). Control and aMCI adults showed
differences for MMN component (— aMCI, . . . healthy controls).
Table 2 |The effects of electrode location and group on ERP amplitude
and latency.
Variable Electrode site Group Location×group
MMN amplitude 25.770*** 0.688 2.586
MMN latency 61.984*** 197.573*** 11.728***
This is the main effect (electrode site, group) and interaction effect (electrode
site×group) using a two-factor analysis of variance.
Electrode site: FZ, FCZ, CZ; Group: MCI vs. HC.
***Indicates p<0.001.
in Lindin et al. were from the middle-aged subgroup (50–64 years),
the MMN from the older age subgroup (65 years and over) was not
that prominent either in Mónica Lindín et al.
The MMN latencies obtained from all three electrode sites (FZ,
FCZ, and CZ) were significantly longer in the aMCI group than
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Table 3 | Comparison of MMN latency between aMCI and healthy
controls.
Electrode Latency
aMCI Controls P
FZ 237.47±9.145 197.44±14.730 <0.001
FCZ 227.16±9.947 196.56±13.191 <0.001
CZ 214.21±17.246 188.26±13.510 <0.001
This is the post hoc test results of the mean values of latencies between aMCI
and control groups.
in the CG, and the difference is more obvious at the FZ electrode
site. This result is intriguing because different results about MMN
latencies were reported in the only two previous studies compar-
ing MCI group with a control group. Lindin et al. (2013) reported
that the MMN latency was significantly shorter in the aMCI group
than in the CG. Mowszowski et al. (2012) also observed slightly
shorter (but non-significant) MMN latencies (measured at Fz and
Cz electrodes) in the MCI than in the control group. Despite the
controversy with the two previous studies, the result of the present
study on MMN latency is consistent with previous studies com-
paring other diseases that may cause cognitive impairment with
a control group. Cai et al. (2004) evaluated MCI in Parkinson’s
disease with MMN and found that the peak latency of MMN in
the PD group was significantly longer than in the control group.
Kathmann et al. (1995) reported delayed MMN peak latencies
in chronic alcoholics, in comparison with their healthy peers.
Lou et al. (2006) evaluated MMN of patients with first-episode
schizophrenia and reported delayed MMN latency in schizophren-
ics compared to healthy controls, similar results were found in
another research in chronic soldiers’ schizophrenics (Gao et al.,
2007). Moreover, prolonged latencies were reported in experimen-
tal group in the clinical researches of MMN in patients with AD
(Chen et al., 2003).
Inconsistent with the two previous studies comparing MCI
group with a control group, no significant group factor was found
in MMN amplitude in the present study. Mowszowski et al. (2012)
observed a larger MMN amplitude in healthy adults than in a
multi-domain MCI group (for an age range of 50–90 years in both
groups). Mónica Lindín et al. found the MMN amplitude was
significantly larger in the CG than the aMCI group, only for the
middle-aged subgroup (50–64 years), but not for adults 65 years
old or more. The authors tentatively speculate that this is probably
due to a significant age-related decrease in MMN amplitude in the
CG, as also found by Gaeta et al. (1998). The lack of differences
between the CG and the aMCI group may be due to an age-related
decline in the mechanism for echoic memory trace maintenance
and/or the pre-attentional mechanisms involved in the automatic
detection of differences in the acoustic environment, which may
mask the effects of aMCI on that parameter (Lindin et al., 2013).
This might also be the reason of the present study of no significant
group factor in MMN amplitude. Further studies are needed to
identify this.
As found in the present study, MMN latencies were significantly
longer in aMCI adults, the MMN latency may be considered a
biomarker of aMCI. Moreover, the characteristics of the MMN
component make it an ideal biomarker; it is an automatic ERP
component, which is not dependent on the attention given by the
subject to the task and, moreover, it is obtained in a non-invasive
manner and is simple and inexpensive to measure. However, in
consideration of the discordance between our findings and the two
previous studies, which reported earlier (latency) and/or smaller
(amplitude) MMNs in the aMCI population (Mowszowski et al.,
2012; Lindin et al., 2013), both contrary to the findings of our
study, a more in-depth approach to potential ways to address this
discordance in future work would be needed to clarify whether
MMN latency can be a fairly sensitive and specific psychophysio-
logical biomarker for the identification of adults with aMCI.
This study is not without limitations that mainly include
unknown group differences in risk factors of cognitive decline
and AD, such as apolipoprotein E e4 genotype, and inflammation,
although there were no significant differences between groups in
terms of gender, age, or educational level. Besides, in consideration
of the relatively small sample size of this study, reference values of
MMN latency and amplitude for both aMCI and healthy elders
could not be offered. Future studies, with a large sample of par-
ticipants, should determine reference values of MMN latency and
amplitude for aMCI elders.
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